Evidence map›Paper›PMID 40560491›Full record

ArticleMolecular and cellular biochemistry2025

Elexacaftor/tezacaftor/ivacaftor (ETI) therapy modifies the expression of interferon beta and inflammatory genes in the airways of adult patients with cystic fibrosis: a pilot study.

Camilla Bitossi, Federica Frasca, Alessandra D'Auria, Matteo Fracella, Giulia Radocchia, Maria Trancassini, Laura Petrarca, Domenico La Regina, Patrizia Troiani, Massimo Gentile and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular and cellular biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Antiviral defenses are diminished at birth in cystic fibrosis pig airways.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Camilla BitossiVirology Laboratory, Department of Molecular Medicine, "Sapienza" University of Rome, 00185, Rome, Italy. camilla.bitossi@uniroma1.it.
Federica FrascaVirology Laboratory, Department of Molecular Medicine, "Sapienza" University of Rome, 00185, Rome, Italy.
Alessandra D'AuriaVirology Laboratory, Department of Molecular Medicine, "Sapienza" University of Rome, 00185, Rome, Italy.
Matteo FracellaVirology Laboratory, Department of Molecular Medicine, "Sapienza" University of Rome, 00185, Rome, Italy.
Giulia RadocchiaDepartment of Public Health and Infectious Diseases, "Sapienza" University of Rome, 00185, Rome, Italy.
Maria TrancassiniDepartment of Public Health and Infectious Diseases, "Sapienza" University of Rome, 00185, Rome, Italy.
Laura PetrarcaDepartment of Maternal, Infantile and Urological Sciences, "Sapienza" University of Rome, 00161, Rome, Italy.
Domenico La ReginaDepartment of Maternal, Infantile and Urological Sciences, "Sapienza" University of Rome, 00161, Rome, Italy.
Patrizia TroianiLazio Reference Center for Cystic Fibrosis, Hospital "Policlinico Umberto I", "Sapienza" University of Rome, 00161, Rome, Italy.
Massimo GentileVirology Laboratory, Department of Molecular Medicine, "Sapienza" University of Rome, 00185, Rome, Italy.
Valeria PietropaoloDepartment of Public Health and Infectious Diseases, "Sapienza" University of Rome, 00185, Rome, Italy.
Fabio MidullaDepartment of Maternal, Infantile and Urological Sciences, "Sapienza" University of Rome, 00161, Rome, Italy.
Giuseppe CiminoLazio Reference Center for Cystic Fibrosis, Hospital "Policlinico Umberto I", "Sapienza" University of Rome, 00161, Rome, Italy.
Guido AntonelliVirology Laboratory, Department of Molecular Medicine, "Sapienza" University of Rome, 00185, Rome, Italy.
Alessandra PierangeliVirology Laboratory, Department of Molecular Medicine, "Sapienza" University of Rome, 00185, Rome, Italy.
Carolina ScagnolariVirology Laboratory, Department of Molecular Medicine, "Sapienza" University of Rome, 00185, Rome, Italy.

Funding

"Sapienza" University of Rome, Italy MA218164304DC6CD"Sapienza" University of Rome, Italy RM1221814ED155C3
6 · The paper itself

Abstract

Cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies have revolutionized the treatment of cystic fibrosis (CF) by targeting the underlying protein defect. Investigating how elexacaftor/tezacaftor/ivacaftor (ETI) therapy affects interferon (IFN) signalling and inflammatory cytokine production in CF airway epithelial cells may clarify its role in alleviating the dysregulated innate immune response. Clinical efficacy was evaluated in 26 modulator-naive CF patients with at least one F508del mutation before and after 3 and 6 months of ETI treatment. Type I/III IFNs, IFNLR1, IFN-stimulated genes (ISG15, ISG56), interleukin 8 (IL-8) and IL-1β mRNA levels were analysed by RT real-time PCR in CF airway samples (n = 74). Patients showed significant improvements in pulmonary function (ppFEV1, 3 months: 12.5%, 6 months: 17.6%), BMI (3 months: 0.9 kg/m

Indexed as

AminophenolsBenzodioxolesCystic FibrosisGene Expression RegulationIndolesInterferon-betaPyrazolesPyridinesPyrrolidinesQuinolonesAdolescentAdultCystic Fibrosis Transmembrane Conductance RegulatorDrug CombinationsFemaleHumansAminophenolsBenzodioxolesCystic Fibrosis Transmembrane Conductance RegulatorDrug CombinationselexacaftorIndolesInterferon-betaivacaftorPyrazolesPyridinesPyrrolidinesQuinolonesCFTR modulator therapiesCystic fibrosisETIIFN betaIFN lambdaIL-1βIL-8InflammationISG15 and ISG56

Identifiers

PMID40560491
PMCPMC12515220

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.